New diagnostic definition of myocardial infarction issued

New diagnostic definition of myocardial infarction issued
An updated universal definition of myocardial infarction includes detection of a rise and/or fall in cardiac biomarker values, preferably cardiac troponin, according to a statement published online Aug. 26 in Circulation to coincide with presentation at the annual European Society of Cardiology Congress, held from Aug. 25 to 29 in Munich.

(HealthDay)—An updated universal definition of myocardial infarction (MI) includes detection of a rise and/or fall in cardiac biomarker values, preferably cardiac troponin (cTn), according to a statement published online Aug. 26 in Circulation to coincide with presentation at the annual European Society of Cardiology Congress, held from Aug. 25 to 29 in Munich.

Kristian Thygesen, Ph.D., from the Aarhus University Hospital in Denmark, and colleagues on the Joint /American College of Cardiology Foundation//World Heart Federation Task Force for the Universal Definition of created the revised definition to be used to better diagnose patients and define clinical trial end points.

The Joint Task Force defined an acute MI as evidence of consistent with acute myocardial ischemia. In this case, the criteria for MI are met with detection of a rise and/or fall of cardiac biomarker values, ideally cTn, with one or more value above the 99th percentile upper reference limit, in conjunction with at least one of the following: symptoms of ischemia; new or presumed new significant ST-segment-T wave changes or new left bundle branch block; development of pathologic Q waves; imaging evidence of new loss of myocardium or abnormality of regional wall motion; or identification of an intracoronary thrombus. In addition, specific criteria are provided for percutaneous coronary intervention-, stent thrombosis-, and grafting-related MIs.

"This is a truly global document that will be used worldwide," Thygesen said in a statement. "It will help doctors diagnose their patients so that they can provide the most appropriate treatment, and help researchers design clinical trials with standardized end points."

Several Task Force members and additional contributors disclosed financial ties to the pharmaceutical and biomedical industries.

More information: Full Text
More Information

add to favorites email to friend print save as pdf

Related Stories

QRS width on ECG linked to sudden cardiac arrest in CAD

Apr 20, 2012

(HealthDay) -- For patients with coronary artery disease (CAD), QRS width on electrocardiogram and echocardiographic evidence of heart failure are associated with out-of-hospital sudden cardiac arrest (SCA), ...

Recommended for you

Time to take notice and tackle heart failure

12 hours ago

Experts have sounded a call to action for policy makers at local, national, and international levels to promote heart failure prevention, improve heart failure awareness among healthcare professionals, ensure ...

Hopes dashed for an agent to prevent reperfusion injury

15 hours ago

The administration of an experimental agent known as TRO40303 to patients who have had a heart attack, with the hope of preventing tissue damage when impaired blood flow is corrected (reperfusion), was disappointingly ineffective ...

User comments